USP8 and neoplasm: Our results demonstrated that although USP8 inhibitor treatment could significantly suppress the Pd-l1-deficient CT26 tumor growth, there was no further additive effect when combined with anti-PD-L1 treatment (Supplementary Fig. 7m).